Roanna Ruiz

Stock Analyst at Leerink Partners

(0)
# 4435
Out of 5,291 analysts
76
Total ratings
31.58%
Success rate
-14.17%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
Xeris Biopharma Hold...
Maintains: Outperform
5 6
5.43 10.5% 5 Mar 7, 2025
Cormedix
Initiates Coverage On: Outperform
18
6.3 185.71% 1 Mar 7, 2025
Lexicon Pharmaceutic...
Downgrades: Market Perform
1
0.63 58.73% 1 Mar 4, 2025
Vir Biotechnology
Maintains: Outperform
18 20
6.53 206.28% 4 Jan 13, 2025
ARS Pharmaceuticals
Maintains: Outperform
26 27
12.47 116.52% 4 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
2.92 345.21% 3 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
14
4.89 186.3% 1 Apr 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
330
304.9 8.23% 1 Feb 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
58
40.62 42.79% 1 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
25
101.42 -75.35% 1 Apr 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
9 2
n/a n/a 4 Apr 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Perform
49
5.44 800.74% 10 Feb 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
2.58 403.88% 7 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
8 6
3 100% 6 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
19
20.58 -7.68% 1 Dec 20, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
110 120
97.63 22.91% 3 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
75 50
8.23 507.53% 7 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
23 27
n/a n/a 7 Oct 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
3 2
0.44 354.55% 6 Oct 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
720 80
n/a n/a 3 Jul 14, 2022